Seddon, B., Strauss, S. J., Whelan, J., Leahy, M., Woll, P. J., Cowie, F., Rothermundt, C., Wood, Z., Benson, C., Ali, N., Marples, M., Veal, G. J., Jamieson, D., Küver, K., Tirabosco, R., Forsyth, S., Nash, S., Dehbi, H., & Beare, S. (n.d.). gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet oncology, 18(10), 1397–1410. http://access.bl.uk/ark:/81055/vdc_100050154261.0x000006